An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 22, 2025

Primary Completion Date

April 24, 2025

Study Completion Date

April 24, 2025

Conditions

Patients on Hemodialysis

Interventions

DRUG

TS-172

oral administration of TS-172 20 mg

Trial Locations (1)

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors

lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT06849778 - An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis | Biotech Hunter | Biotech Hunter